Cancer Res Treat.  2001 Oct;33(5):377-384.

Combination Chemotherapy with Mitomycin C, Vinorelbine, and Cisplatin (MVrP) in Patients with Advanced Non-Small Cell Lung Cancer

• Kim HG
• Lee GW
• Lee DH
• Hwang IG
• Shim KS
• Lee WS
• Lee JD
• Jang JS
• Hwang YS
• Lee JS

Abstract

PURPOSE: A phase II study was conducted in patients with advanced non-small cell lung cancer (NSCLC) in order to evaluate the efficacy and toxicity of the combination chemotherapy regimen of mitomycin C, vinorelbine, and cisplatin (MVrP).
MATERIALS AND METHODS
Between June 1996 and December 2000, fifty-nine patients with unresectable stage IIIB to IV, pathologically documented NSCLC were enrolled in this study. One cycle consisted of mitomycin C 10 mg/m2 i.v. day 1, vinorelbine 30 mg/m2 i.v. days 1 & 15, and cisplatin 80 mg/m2 i.v day 1 and the next cycle consisted of vinorelbine 30 mg/m2 i.v. days 29 & 43, and cisplatin 80 mg/m2 i.v day 29. Each cycle was alternated and treatments were repeated every 8 weeks.
RESULTS
We were able to evaluate fifty-three of 59 patients. Objective responses were seen in 22 (41.5%) patients (CR 0%, PR 41.5%). The median duration of response was 13.7 weeks and the median time to progression was 17.7 weeks. The median overall survival was 45.6 weeks. There was a significantly longer survival seen in responders (p=0.041). The toxicities of this regimen were acceptable without treatment related toxic death.
CONCLUSION
This study suggests that a combination regimen of mitomycin C, vinorelbine, and cisplatin is relatively effective and well tolerated for the treatment of advanced NSCLC.

Keyword

Non-small cell lung cancer; Combination chemotherapy; Mitomycin C; Vinorelbine; Cisplatin

MeSH Terms

Carcinoma, Non-Small-Cell Lung*
Cisplatin*
Drug Therapy, Combination*
Humans
Mitomycin*
Cisplatin
Mitomycin